<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369262</url>
  </required_header>
  <id_info>
    <org_study_id>17-OBE022-003</org_study_id>
    <nct_id>NCT03369262</nct_id>
  </id_info>
  <brief_title>PoC Study of OBE022 in Threatened Preterm Labour</brief_title>
  <acronym>PROLONG</acronym>
  <official_title>A Phase 2a, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of OBE022 added-on to Atosiban, After Oral Administration in Pregnant Women With Threatened Spontaneous Preterm Labour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ObsEva SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ObsEva SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof-of-concept study in 2 parts.

      In Part A, patients will receive OBE022 open-label in order to assess the safety and
      pharmacokinetics in pregnant women with spontaneous preterm labour with a gestational age
      between 28 0/7 and 33 6/7 weeks.

      Part B has a double-blind, randomised, placebo controlled, parallel group and multicentre
      design and will assess the efficacy, safety and pharmacokinetics in pregnant women with
      threatened spontaneous preterm labour with a gestational age between 24 0/7 and 33 6/7 weeks.

      All patients in part A and part B must receive atosiban infusion for 48 hours as standard of
      care treatment. Patients from Part A will receive OBE022 open label. Patients from Part B
      will be randomised to receive OBE022 or matching placebo. IMP treatment duration will be up
      to 7 days. IMP treatment will be stopped in case of delivery prior to Day 7.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A phase 2a, double-blind, parallel group, randomised, placebo controlled, added-on to atosiban.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Matching placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of delivery within 2 days (48 h) from start of IMP administration</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of delivery within 7 days (168 h) from start of IMP administration</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of delivery before 37 weeks of GA</measure>
    <time_frame>Up to 13 weeks from start of IMP administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to delivery measured from start of IMP administration</measure>
    <time_frame>Up to 17 weeks from start of IMP administration</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Maternal incidence of AEs from Day 1 until 28 days after birth.</measure>
    <time_frame>28 days after birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal incidence of TEAEs from Day 1 until 28 days after birth.</measure>
    <time_frame>28 days after birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal incidence of clinically significant changes in laboratory safety tests, from Day 1 until 28 days after birth.</measure>
    <time_frame>28 days after birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal incidence of clinically significant changes in vital signs, from Day 1 until 28 days after birth.</measure>
    <time_frame>28 days after birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of AEs indicating fœtal distress such as growth retardation and/or changes in fœtal heart rate monitoring and/or amniotic fluid index (AFI) from Day 1 to Day 7 and Day 14 (or earlier if birth).</measure>
    <time_frame>Up to 14 days after start of IMP administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>In Part A only: Pulsatility index of the ductus arteriosus on Day 1 to 3 and Day 7 from IMP start.</measure>
    <time_frame>Up to 7 days after start of IMP administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>In Part A only: Foetal combined cardiac output on Day 1 to 3 and Day 7 from IMP start.</measure>
    <time_frame>Up to 7 days after start of IMP administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of infants experiencing adverse events from birth until 28 days after birth.</measure>
    <time_frame>Up to 28 days after birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of infants experiencing clinical significant changes in vital signs from birth until 28 days after birth.</measure>
    <time_frame>Up to 28 days after birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apgar score.</measure>
    <time_frame>At birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Weight.</measure>
    <time_frame>At birth and 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Head circumference.</measure>
    <time_frame>At birth and 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of stillborn.</measure>
    <time_frame>At birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of neonatal death.</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of duration of hospitalization and or re-admission to hospital</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of assisted ventilation</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of respiratory distress syndrome</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of bronchopulmonary dysplasia.</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of grade 1-4 intra-ventricular haemorrhage.</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of periventricular leukomalacia or periventricular echogenicity</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of renal impairment</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of cardiac abnormalities</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of necrotizing enterocolitis</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of difficulty in thermoregulation</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of difficulty in feeding</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of jaundice</measure>
    <time_frame>Up to 28 days after birth.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of infants with one or more Ages and Stages Questionnaire® domain score(s) below the cut-off score at 6 months, 12 months and 24 months of age, adjusted for gestational age at birth.</measure>
    <time_frame>Up to 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma concentration of OBE022/OBE002 at Day 1, Day 2, Day 3 and Day 7.</measure>
    <time_frame>Up to 7 days after start of IMP administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the curve (AUC).</measure>
    <time_frame>Day 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximal concentration (Cmax).</measure>
    <time_frame>Day 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half-life.</measure>
    <time_frame>Day 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fœtal (cord blood)-maternal OBE002 concentration ratio at the time of delivery for patients who received IMP treatment within the previous 24 h.</measure>
    <time_frame>Day of delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in uterine contractions as assessed by electrohysterography, tocodynamometry or abdominal palpation at each hour during the first 6 hours after IMP start.</measure>
    <time_frame>Up to 6 hours after IMP start.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose from Part A. Plus Atosiban as per label.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OBE022 matching placebo. Plus Atosiban as per label.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OBE022</intervention_name>
    <description>Oral</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atosiban</intervention_name>
    <description>I.V.</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Part A

          -  Pregnant females aged ≥ 18 years

          -  Patients with a singleton or twin pregnancy

          -  Gestational age between 28 0/7 and 33 6/7

          -  Administered or prescribed atosiban for the treatment of preterm labour

        Part B

        Additional inclusion criteria required:

          -  ≥4 uterine contractions per 30 minutes

          -  Cervical dilatation of 1 to 4 cm inclusive

          -  At least one of the following consequences of preterm labour:

               1. positive IGFBP-1 or fœtal Fibronectin test

               2. cervical length ≤ 25mm

               3. progressive cervical change

        Key Exclusion Criteria:

          -  Fœtal death in utero in current or previous pregnancy after gestational week 24 or
             expected high risk of fœtal death in the coming days

          -  Oligohydramnios

          -  Pathological Doppler ultrasound of the umbilical artery

          -  Any contraindications for the mother or the fœtus to stop labour or prolong pregnancy
             or any maternal or fœtal conditions likely to indicate iatrogenic delivery in the next
             7 days, including but not limited to:

               1. Premature rupture of membranes

               2. Evidence or suspicion of abruptio placenta

               3. Signs and/or symptoms of chorio-amnionitis

               4. Pre-eclampsia, eclampsia or HELLP-syndrome

          -  Use of cervical cerclage in the current pregnancy or a pessary in situ

          -  Current use of anti-hypertensive medication

          -  Treatment with other tocolytics within specified time before the baseline assessment
             of uterine contractions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Director</last_name>
    <phone>+41 (0)22 552 3840</phone>
    <email>clinicaltrials@obseva.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki Universisty Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>preterm labor</keyword>
  <keyword>preterm birth</keyword>
  <keyword>premature birth</keyword>
  <keyword>tocolysis</keyword>
  <keyword>prostaglandin F2α antagonist</keyword>
  <keyword>PGF2α</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atosiban</mesh_term>
    <mesh_term>Vasotocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

